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We aimed to create a prognostic model in metastatic melanoma based on independent prognostic factors in 321 patients receiving
interleukin-2 (IL-2)-based immunotherapy with a median follow-up time for patients currently alive of 52 months (range 15–189
months). The patients were treated as part of several phase II protocols and the majority received treatment with intermediate dose
subcutaneous IL-2 and interferon-a. Neutrophil and monocyte counts, lactate dehydrogenase (LDH), number of metastatic sites,
location of metastases and performance status were all statistically significant prognostic factors in univariate analyses. Subsequently,
a multivariate Cox’s regression analysis identified elevated LDH (Po0.001, hazard ratio 2.8), elevated neutrophil counts (P¼0.02,
hazard ratio 1.4) and a performance status of 2 (P¼0.008, hazard ratio 1.6) as independent prognostic factors for poor survival. An
elevated monocyte count could replace an elevated neutrophil count. Patients were assigned to one of three risk groups according to
the cumulative risk defined as the sum of simplified risk scores of the three independent prognostic factors. Low-, intermediate- and
high-risk patients achieved a median survival of 12.6 months (95% confidence interval (CI), 11.4–13.8), 6.0 months (95% CI, 4.8–7.2)
and 3.4 months (95% CI, 1.2–5.6), respectively. The low-risk group encompassed the majority of long-term survivors, whereas the
patients in the high-risk group with a very poor prognosis should probably not be offered IL-2-based immunotherapy.
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The prognosis for patients with metastatic melanoma is poor with
a median survival time between 4 and 12 months (Barth et al,
1995). Interleukin-2 (IL-2) has resulted in durable responses and
cure in 5–7% of the patients (Rosenberg et al, 1998; Atkins et al,
2000). Meta-analyses on patients receiving IL-2-based immuno-
therapy have identified independent prognostic factors of survival
such as serum lactate dehydrogenase (LDH), number of metastatic
sites and performance status (Eton et al, 1998; Keilholz et al, 1998,
2002; Manola et al, 2000). Presently, the strongest prognostic factor
in metastatic melanoma is LDH, which is used in the American
Joint Committee on Cancer (AJCC) stage IV classification in
combination with site of metastases (Balch et al, 2001a).
The new paradigm in tumour immunology states that tumour-
infiltrating inflammatory cells such as macrophages and neutro-
phils play a pivotal role in tumour progression and dissemination
in a wide range of cancers (Balkwill and Mantovani, 2001;
Coussens and Werb, 2002; Pollard, 2004). Recently, baseline
elevated neutrophil and monocyte counts in peripheral blood were
proposed as prognostic factors for poor survival in patients with
metastatic renal cell carcinoma undergoing immunotherapy with
IL-2 or a-interferon-2b (IFN) (Negrier et al, 2002; Atzpodien et al,
2003; Donskov et al, 2004). Similar data are not available in
metastatic melanoma.
We have examined the prognostic impact of neutrophils and
monocytes in peripheral blood together with other potentially
prognostic factors in 321 patients with metastatic melanoma
receiving IL-2-based immunotherapy in consecutive clinical trials
between 1990 and 2003. Based on independent prognostic factors,
we propose a prognostic model for metastatic melanoma.
MATERIAL AND METHODS
Patients
Between April 1990 and December 2003, 321 patients with
metastatic melanoma were entered on consecutive clinical trials
with IL-2-based immunotherapy. Data were analysed per 1
February 2005, that is, more than 1 year after the last patient
had received IL-2-based immunotherapy. The main inclusion
criteria consisted of biopsy-verified stage IV disease, a WHO
performance status of 2 or better and age above 18 years. The main
exclusion criteria were brain metastases, a previous malignant
disease other than nonmelanoma skin cancer, symptomatic heart
or lung disease, seizure disorders, serious autoimmune disorders,
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sconcomitant corticosteroid therapy or previous systemic treatment
for metastatic disease. The ethics committees at the involved
counties approved the present project, and written informed
consent was obtained from each patient. Data were collected from
the three participating institutions, and all cases were reviewed
individually and entered in a central database. The data set was
complete with the exception of one missing monocyte count from
a single patient.
Treatments
In all, 20 patients received recombinant IL-2 and IFN. Interleukin-
2 was administered at a dose of 18MUm
 2day
 1 by a 24-h conti-
nuous intravenous (i.v.) infusion. Interferon was administered
during the IL-2 infusion periods at a dose of 3MUm
 2day
 1.
The treatment plan consisted of two induction cycles and four
maintenance cycles with a 3-week rest period following each
cycle. Each induction cycle consisted of two IL-2 infusion periods
of 120 and 108h duration, respectively, separated by 6 days
rest period. Each maintenance cycle consisted of a 120h IL-2
infusion period.
In all, 86 patients received IL-2, IFN and cisplatinum (Schmidt
et al, 2000). One cycle consisted of cisplatinum i.v. bolus on day 1
at a dose of 100mgm
 2. Recombinant IL-2 was administered
subcutaneous (s.c.) at a dose of 9MUm
 2 twice daily on days 5–9
and at a dose of 4.5MUm
 2 daily on days 12, 14 and 16. Interferon
was administered s.c. at a dose of 10MU daily on days 2–4 and
thereafter three times weekly.
In total, 83 patients received IL-2, IFN7histamine (Schmidt
et al, 2002). One cycle consisted of IL-2 s.c. at a dose of 9MU twice
daily on days 4–8, and daily on days 11–15. Patients received
INF at a dose of 5MU s.c. daily from days 1 to 21. Histamine
dihydrochloride was administered s.c. at a dose of 1mg over
20min, twice daily. Histamine injections were administered from
day 4 and on the same days as IL-2 and INF injections.
A total of 102 patients received IL-2 s.c.7low-dose total body
irradiation (LTBI). One cycle consisted of IL-2 s.c. on days 2–5 at
a dose of 18MU twice daily, and at a dose of 9MU twice daily on
days 9–12. A single fraction of LTBI 0.1Gy were given on days
1 and 8.
In all, 30 patients received intratumoral injections of bleomycin
and electroporation (electrochemotherapy) followed by IL-2 s.c.
at a dose of 2MU daily for 21 consecutive days (Gehl et al, 2003).
Statistics
Calculations were performed using SPSS (version 11.5) statistical
software. Univariate and multivariate Cox’s analyses were per-
formed to investigate the prognostic impact of baseline factors
in relation to survival. Factors included were WHO performance
status (0–1 vs 2); number of metastatic sites (1–2 vs X3); site of
metastases (skin and lymph nodes vs lungs vs other visceral sites);
baseline serum LDH (normal vs elevated); baseline blood neutro-
phil counts (normal vs elevated); and baseline blood monocyte
counts (normal vs elevated). Baseline blood measurements (LDH,
neutrophils and monocytes) were both analysed as continuous
variables (absolute values) and as dichotomous variables using
the upper normal reference level from each of laboratories in the
participating institutions. Survival was calculated from the day
of treatment start to the end point (death or censoring). Patient
survival and median duration of response was analysed by the
Kaplan–Meier method. The simultaneous relationship of multiple
prognostic factors for survival was assessed using Cox’s proportional-
hazards model. Factors with a P-value o0.10 in the univariate
analyses were included in the multivariate analysis to identify
factors of independent significance. The multivariate analysis was
stratified according to treatment regimens. The multivariate model
selection was performed by a stepwise strategy using the likelihood
ratio test to create a multiple risk factor model. Hazard ratios
were calculated to estimate the magnitude and the direction
of the effect. Schoenfeld residuals and log( log(S)) vs t plots
were evaluated to assure the assumption of proportional
hazards. Assessment of the model was carried out using cross-
validation techniques (Altman and Royston, 2000), using SAS
(version 8.2) statistical software. All survival data were updated on
1 February 2005.
RESULTS
The median survival was 8.1 months (range 1–188), and 19 of 321
patients were currently alive. Of these 19 patients, 17 had a survival
length of more than 24 months and were termed long-term
survivors. Data were analysed more than 1 year after the last
patient had received IL-2-based immunotherapy and the median
follow-up time of the 19 patients currently alive was 52 months
(range 15–188 months).
Univariate analyses of pretreatment variables
In univariate analyses, the following baseline factors were
statistically significantly (Po0.05) associated with poor survival:
elevated LDH (Po0.001), a performance status of 2 (Po0.001),
elevated neutrophil counts (Po0.001), elevated monocyte counts
(Po0.001) (Figure 1A–D), more than two metastatic sites
(Po0.001) and site of metastases (P¼0.03) (Table 1). Elevated
LDH, neutrophil and monocyte counts refer to levels above the
upper normal reference levels.
Multivariate analyses of pretreatment variables
Upon entering the significant variables from the univariate
analyses into a multivariate Cox’s analysis, three variables turned
out as independent factors of poor survival: elevated LDH
(Po0.001), elevated neutrophil counts (P¼0.02) and a perfor-
mance status of 2 (P¼0.008) (Table 2). Similar results were
achieved when entering blood counts as absolute values (data not
shown). In patients with a normal LDH, the 5-year survival rate
was 9% compared to 0% in patients with an elevated LDH
(Figure 1A). Similarly, in patients with a normal neutrophil count,
the 5-year survival rate was 7% compared to 0% in patients with an
elevated count (Figure 1C). Model assessment using crossvalida-
tion revealed that the model was robust, and there was little
evidence of overfitting. The alternative multivariate model
including monocytes, instead of neutrophils, yielded a similar
result (likelihood ratio w
2 of 87.7 vs 86.6).
Prognostic model
Based on the ratios of regression coefficients (log hazard ratios
in the final Cox’s model) of variables, we defined the weights of
prognostic factors as follows: elevated LDH was assigned weight 2,
elevated neutrophil counts weight 1 and performance status of
2 weight 1. A prognostic score of the cumulated weights of these
variables was used to assign patients to low-risk (none elevated,
score 0), intermediate-risk (any combination of 1–2 elevated
variables, score 1–3) and high-risk (all three variables elevated,
score 4) groups, respectively. The median survival of low-risk
(n¼139), intermediate-risk (n¼161) and high-risk patients (n¼21)
was 12.6 months (95% confidence interval (CI) 11.4–13.8), 6.0
months (95% CI, 4.8–7.2) and 3.4 months (95% CI, 1.2–5.6),
respectively (Figure 2A). The 5-year survival rates for these three
groups were 9, 1 and 0%, respectively. The predicted 12-month
survival probabilities were similar to the respective Kaplan–Meier
estimates for each risk score. The 12-month survival probabilities
predicted by the Cox’s model were 48% (low risk), 14%
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Figure 1 Kaplan–Meier survival estimates for 321 patients with metastatic melanoma according to baseline: (A) lactate dehydrogenase (LDH), (B)
performance status, (C) blood neutrophils and (D) blood monocytes.
Table 1 Univariate Cox’s analyses of risk factors and survival in metastatic melanoma
Univariate Cox’s analyses
Risk factors Categories compared Number of patients Hazard ratio 95% CI P-value
Gender Female vs male 181 vs 140 1.0 0.8–1.3 0.88
Age (median 51 years) o51 vs X51 157 vs 164 1.1 0.9–1.3 0.59
Performance status 0–1 vs 2 272 vs 49 2.1 1.5–2.8 o0.001
No. of metastatic sites 1–2 vs X3 195 vs 126 1.6 1.3–2.0 o0.001
Location of metastases Skin, lymph nodes vs lung vs visceral sites 82 vs 72 vs 167 0.03*
Skin, lymph nodes vs lung 82 vs 72 1.3 0.9–1.8 0.11
Skin, lymph nodes vs visceral sites 82 vs 167 1.5 1.1–1.9 0.01
LDH Normal vs elevated 174 vs 147 2.9 2.3–3.7 o0.001
Neutrophil counts Normal vs elevated 237 vs 84 1.9 1.4–2.4 o0.001
Monocyte counts Normal vs elevated 217 vs 103 1.7 1.4–2.2 o0.001
CI¼confidence interval; LDH¼lactate dehydrogenase. *P-value is an overall estimate for all levels.
Neutrophils and monocytes in metastatic melanoma
H Schmidt et al
275
British Journal of Cancer (2005) 93(3), 273–278 & 2005 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s(intermediate risk) and 1% (high risk), and the Kaplan–Meier
estimates were 51, 13 and 0%, respectively. Similar differences
were observed for the 24-month survival probabilities.
We compared our proposed prognostic model with the current
AJCC classification of stage IV disease, which includes LDH, and
also the site of metastases. The AJCC model defines stage M1a
as skin or lymph node metastases with a normal LDH, M1b as
lung metastases with a normal LDH and M1c as other visceral
metastases or an elevated LDH. In the univariate analyses, we
found a significant difference in survival time between stage M1a
and M1c (Po0.001), but not between M1a and M1b (P¼0.11)
(Figure 2B). When entering the AJCC model together with our
proposed model into a multivariate analysis, the prognostic index
of LDH, neutrophils and performance status remained highly
statistically significant through all levels (Po0.001), while the
AJCC classification (P¼0.26) had no independent prognostic
impact (Table 3).
DISCUSSION
Recent studies of IL-2-based immunotherapy in metastatic
melanoma have identified mainly LDH, performance status,
number of metastatic sites and sites of metastases as independent
prognostic factors (Sirott et al, 1993; Eton et al, 1998; Keilholz
et al, 1998, 2002; Manola et al, 2000). Our findings of LDH and
performance status as independent prognostic factors were
therefore expected. However, the prognostic impact of neutrophils
and monocytes in peripheral blood was a novel finding. Both
elevated neutrophil and monocyte counts were associated with
poor survival in the univariate analyses, and if neutrophils were
forced out of the multivariate model, monocytes became an
independent prognostic factor together with LDH and perfor-
mance status. The neutrophil and monocyte counts were highly
significantly correlated in the patient material (Spearman’s rank-
correlation coefficient 0.49, Po0.0001), which explains why only
one of them was an independent factor in the multivariate analysis.
Thus, the neutrophil count could be replaced by the monocyte
count resulting in a similar prognostic score.
Our findings in patients with metastatic melanoma correspond
with observations in metastatic renal cell carcinoma. Thus, an
elevated neutrophil count was an independent risk factor for poor
survival in two large studies in metastatic renal cell carcinoma
(Negrier et al, 2002; Atzpodien et al, 2003), whereas the monocyte
count was not considered in these studies. In a third study, both
elevated neutrophil and elevated monocyte counts were statisti-
cally significant correlated to poor survival however, in univariate
analyses (Donskov et al, 2004). The explanation for the association
between high neutrophil or monocyte counts and poor prognosis
is not fully clarified. The new paradigm in tumour immunology
states that the tumour microenvironment can educate and control
invading leucocytes to promote angiogenesis, viability, motility
and invasion (Hanahan and Weinberg, 2000; Balkwill and
Mantovani, 2001; Coussens and Werb, 2002; Lin and Pollard,
2004). Especially tumour-associated macrophages, which arise
from blood monocytes, seem to play a crucial role in this inter-
action (Pollard, 2004). The chemokines CXCL1 (Gro-a) and CXCL8
Table 2 Multivariate Cox’s model of independent prognostic factors for survival in metastatic melanoma
Multivariate Cox’s analysis
a
Risk factors
Categories
compared Hazard ratio 95% CI P-value
Regression
coefficients
Weight (contribution to
cumulative risk score)
Performance status 0–1 vs 2 1.6 1.1–2.3 0.008 0.47 0 vs 1
LDH Normal vs elevated 2.8 2.2–3.6 o0.001 1.03 0 vs 2
Neutrophils Normal vs elevated 1.4 1.1–1.8 0.02 0.32 0 vs 1
CI¼confidence interval; LDH¼lactate dehydrogenase. All other variables (location of metastases, number of metastatic sites and blood monocytes) were not significant and
therefore excluded from the model.
aIn all, 320 patients and 301 deaths. Analysis stratified by treatment regimen.
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Figure 2 Kaplan–Meier survival estimates for 321 patients with
metastatic melanoma according to combination factors: (A) prognostic
model with low, intermediate and high risk. (B) AJCC stage IV classification:
M1a, normal lactate dehydrogenase (LDH) and metastases confined to the
skin and lymph nodes, M1b including lung metastases and normal LDH and
M1c including other visceral organs or elevated serum LDH.
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s(IL-8) are constitutively produced by melanoma cells and the
corresponding receptors CXCR1 and CXCR2 are expressed on
melanoma cells as well as on macrophages, neutrophils and
eosinophils (Moser et al, 1993; Norgauer et al, 1996; Dhawan and
Richmond, 2002). The autocrine production of these chemokines
by melanoma cells increases their survival, proliferation and
dissemination, as well as attracts inflammatory cells, such as
monocytes and neutrophils (Haghnegahdar et al, 2000; Schaider
et al, 2003; Balkwill, 2004). These tumour-infiltrating neutrophils
can produce VEGF, IL-8 and matrix metalloproteinases involved
in tumour invasion and angiogenesis (Shamamian et al, 2001;
Schaider et al, 2003). In one study, IL-8 was detectable in the
serum in 50% of patients with metastatic melanoma, which
correlated with tumour load (Scheibenbogen et al, 1995). These
findings indicate a link between elevated neutrophils and
monocytes in peripheral blood and especially aggressive melano-
mas leading to a poor prognosis.
The high-risk group in our proposed prognostic index with
elevated neutrophil counts, elevated LDH and a performance status
of 2, had a very poor prognosis with a median survival of only 3.4
months (95% CI, 1.2–5.6). None of these patients survived for
more than 10 months, and this group of patients should probably
not be offered IL-2-based immunotherapy. In contrast, the low-
risk group with no elevated risk factors had a median survival of
12.6 months (95% CI, 11.4–13.8) and included 15 of the 17 long-
term survivors. It should be emphasised that the majority of
patients in our study were treated with intermediate s.c. IL-2
regimens and these results cannot directly be applied to patients
treated with high-dose i.v. IL-2. However, our hypothesis is that
the findings will be similar for such a group of patients.
We applied our data to the AJCC stage IV classification (version
2001), and observed a significant difference in survival between
patients with skin/lymph node metastases (M1a) and visceral
metastases or an elevated LDH (M1c), but not between M1a and
patients with lung metastases (M1b). These results correspond well
with the data reported by Balch et al (2001b) demonstrating a
significant survival difference between M1a and M1b at 1 year, but
not beyond that time frame. When we tested our prognostic model
against the AJCC model in a multivariate analysis, the prognostic
impact of our model based on neutrophils, LDH and performance
status (Po0.001) was superior compared to the AJCC model
(P¼0.22). Similarly, Keilholz et al (2002) have reported that
the prognostic impact of a combination of LDH and performance
status was superior to the AJCC model. Our results further
supplements that model by adding neutrophil counts. The
proposed model has been internally validated (Altman and
Royston, 2000), but validation in an independent study is
obviously warranted.
In conclusion, the independent prognostic impact of elevated
neutrophil or monocyte counts in peripheral blood is a novel
finding in patients with metastatic melanoma. As expected, LDH
and performance status were also independent prognostic factors.
Our proposed prognostic model with neutrophil counts, LDH
and performance status was able to identify a low-risk group
encompassing the majority of long-term survivors, and a high-risk
group with a very poor prognosis, which should probably
not be offered IL-2-based immunotherapy. The validation of the
prognostic model in an independent study is warranted.
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